Improvement of anti-tumor abilities on human non-small cell lung carcinoma by micellization and cross-linking of N-(2-hydroxypropyl) methacrylamide copolymers

References

• Le Chevalier T. Non-small cell lung cancer: the challenges of the next decade. Front Oncol 2011;1–29. doi:10.3389/fonc.2011.00029
   Google Scholar
• Rosti G, Carminati O, Monti M, et al. Chemotherapy advances in small cell lung cancer. Ann Oncol 2006;17:v99–102
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213–25
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Šubr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev 2010;62:150–66
   PubMed Web of Science ®Google Scholar
• Xiang Q, Yang Y, Zhou Z, et al. Synthesis and in vitro anti-tumor activity of novel HPMA copolymer–drug conjugates with potential cell surface targeting property for carcinoma cells. Eur J Pharm Biopharm 2012;80:379–86
   PubMed Web of Science ®Google Scholar
• He S, Zhou Z, Li L, et al. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer–doxorubicin conjugates. Drug Deliv 2014:1–12 . [Epub ahead of print]. doi:10.3109/10717544.2014.911991
   PubMedGoogle Scholar
• Yang Y, Li L, Zhou Z, et al. Targeting prostate carcinoma by G3–C12 peptide conjugated N-(2-hydroxypropyl) methacrylamide copolymers. Mol Pharm 2014;11:3251–60
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010;62:122–49
   PubMed Web of Science ®Google Scholar
• Bissett D, Cassidy J, De Bono J, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J Cancer 2004;91:50–5
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009;34:1629–36
   PubMed Web of Science ®Google Scholar
• Nowotnik DP, Cvitkovic E. ProLindac™ (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev 2009;61:1214–19
   PubMed Web of Science ®Google Scholar
• Seymour L, Duncan R, Strohalm J, et al. Effect of molecular weight (Mw) of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 1987;21:1341–58
   PubMed Web of Science ®Google Scholar
• Cartlidge SA, Duncan R, Lloyd JB, et al. Soluble, crosslinked N-(2-hydroxypropyl) methacrylamide copolymers as potential drug carriers: 3. Targeting by incorporation of galactosamine residues. Effect of route of administration. J Control Release 1987;4:265–78
   Google Scholar
• Etrych T, Šubr V, Strohalm J, et al. HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity. J Control Release 2012;164:346–54
   PubMed Web of Science ®Google Scholar
• Etrych T, Strohalm J, Chytil P, et al. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. Eur J Pharm Sci 2011;42:527–39
   PubMed Web of Science ®Google Scholar
• Liu J, Zeng F, Allen C. In vivo fate of unimers and micelles of a poly (ethylene glycol)-block-poly (caprolactone) copolymer in mice following intravenous administration. Eur J Pharm Biopharm 2007;65:309–19
   PubMed Web of Science ®Google Scholar
• Kim S, Shi Y, Kim JY, et al. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle–cell interaction. Exp Opin Drug Deliv 2010;7:49–62
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li L, Yang Y, et al. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles. Biomaterials 2014;35:6622–35
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Matsumoto H, Doi Y, et al. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin. Eur J Pharm Biopharm 2012;81:524–31
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73:2412–17
   PubMed Web of Science ®Google Scholar
• Meng H, Xue M, Xia T, et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 2011;5:4131–44
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Šubr V, Strohalm J, et al. Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation. J Control Release 2000;64:63–79
   PubMed Web of Science ®Google Scholar
• Duncan R, Cable HC, Lloyd JB, et al. Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side-chains in poly [N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Die Makromol Chem 1983;184:1997–2008
   Web of Science ®Google Scholar
• Liu XM, Quan LD, Tian J, et al. Synthesis and evaluation of a well-defined HPMA copolymer–dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm Res 2008;25:2910–19
   PubMed Web of Science ®Google Scholar
• Vinci M, Gowan S, Boxall F, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol 2012;10:29
   PubMed Web of Science ®Google Scholar
• Elliott NT, Yuan F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 2011;100:59–74
   PubMed Web of Science ®Google Scholar
• Nyga A, Cheema U, Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 2011;5:239–48
   PubMed Web of Science ®Google Scholar
• Kim TH, Mount CW, Gombotz WR, et al. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 2010;31:7386–97
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076–86
   PubMed Web of Science ®Google Scholar
• Goldberg D, Winfield D. Diagnostic accuracy of serum enzyme assays for myocardial infarction in a general hospital population. Br Heart J 1972;34:597–604
   PubMedGoogle Scholar
• Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction recommendations based on a quantitative analysis. Ann Internal Med 1986;105:221–33
   PubMed Web of Science ®Google Scholar
• Ozer JS, Chetty R, Kenna G, et al. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol 2010;56:237–46
   PubMed Web of Science ®Google Scholar
• Caglar K, Kinalp C, Arpaci F, et al. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant 2002;17:1931–5
   PubMed Web of Science ®Google Scholar